Annals of the Rheumatic Diseases (ARD)

is a leading rheumatology journal from EULAR, publishing original research, reviews and recommendations

Impact Factor: 27.4
Citescore: 32.8
All metrics >>

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via Twitter and Facebook.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Current Issue

Latest EULAR Recommendations

The use of imaging in large vessel vasculitis in clinical practice

EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update

Early stages of diagnosis and management of suspected HLH/MAS

2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome

3D rendered photo of rheumatological disease affecting the hand

Non-pharmacological management of SLE and SSc

EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis

Management of ANCA-associated vasculitis

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.

The Author Information section provides general guidelines and requirements for specific article types.

Information is also provided on editorial policies and open access.

Author information Submit a paper

Editor's Choice

Rheumatoid arthritis:

Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study

24 July 2023

Rheumatoid arthritis:

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

9 July 2023

Review:

Approach to vaccination in systemic lupus erythematosus on biological treatment

19 June 2023

Review:

Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets

15 February 2023

Latest Articles

Recommendation:

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

12 October 2023

Viewpoint:

New approach to testing treatments for osteoarthritis: FastOA

11 October 2023

Letter:

IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis

9 October 2023

Spondyloarthritis:

Card9/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis

9 October 2023

Spondyloarthritis:

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

4 October 2023

Articles by Topic

View full list

Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

All EULAR recommendations are free to access.

Each recommendation also has an accompanying lay summary, which is also free to access.

Video

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

23 August 2023

Conclusions The efficacy of BKZ in bDMARD-naïve patients with PsA was sustained from Week 16 to Week 52. BKZ was well tolerated with no new safety signals observed.

Find out more